Literature DB >> 32890439

Cellular senescence and hepatitis B-related hepatocellular carcinoma: An intriguing link.

Nikolaos D Karakousis1,2, Alkistis Papatheodoridi2,3, Antonios Chatzigeorgiou2,4, George Papatheodoridis1.   

Abstract

Chronic hepatitis B is mainly responsible for the morbidity and mortality from hepatitis B virus (HBV)-related complications, including hepatocellular carcinoma (HCC) and decompensated cirrhosis. Hepatocellular carcinoma remains the main challenge in the management of not only undiagnosed and/or untreated but also diagnosed and treated patients with chronic HBV infection, as its incidence decreases but is not eliminated even after many years of effective anti-HBV therapy. The exact mechanisms used by HBV to cause malignant transformation remain uncertain, although much of the available data are in favour of a pathogenetic role of HBx protein. Senescence is a cellular state, in which cells lose their ability to proliferate. This biological mechanism may function in a dual mode, namely being both cancer-protective as a result of reduced cellular proliferation, but also cancer-enhancing as a result of modulation of the tissular microenvironment by immune cells during persistent accumulation of senescent cells. Protein X of HBV protein exhibits many similarities in terms of the implemented mechanisms of action and pathways related to the biological process of cellular senescence. Concurrently, insufficient clearance of both senescent and precancerous hepatocytes combined with inadequate immune surveillance as a result of immunosenescence caused by chronic HBV infection may lead to hepatocarcinogenesis. Thus, the effect of HBV seems to be critical as a connecting link between cellular senescence and development of HCC. An ongoing research is underway towards identifying and validating markers of hepatocyte senescence, which could improve the landscape for evaluation of chronic liver disease, thereby providing valuable information in terms of HBV-related carcinogenesis.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatitis B virus; hepatocellular carcinoma; hepatocyte senescence; immunosenescence; protein X

Mesh:

Substances:

Year:  2020        PMID: 32890439     DOI: 10.1111/liv.14659

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Clinical, Pathological and Genetic Characteristics of Pediatric Hepatocellular Carcinoma Associated with Hepatitis B Virus Infection.

Authors:  Pan Zhao; Yinying Lu; Chunya Wang; Limin Wang; Jinfeng Li; Meina Li
Journal:  J Hepatocell Carcinoma       Date:  2021-05-10

2.  Exploring the Mechanisms of Arsenic Trioxide (Pishuang) in Hepatocellular Carcinoma Based on Network Pharmacology.

Authors:  Xinmiao Wang; Luchang Cao; Jingyuan Wu; Guanghui Zhu; Xiaoyu Zhu; Xiaoxiao Zhang; Duoduo Han; Ning Shui; Baoyi Ni; Jie Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-29       Impact factor: 2.629

3.  Mulberry fruit polysaccharides alleviate diethylnitrosamine/phenobarbital-induced hepatocarcinogenesis in vivo: the roles of cell apoptosis and inflammation.

Authors:  Shanshan Li; Yang Li; Hongjian Sun; Yang Jiang; Keming Pan; Yue Su; Nan Bu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Development and validation of a novel cellular senescence-related prognostic signature for predicting the survival and immune landscape in hepatocellular carcinoma.

Authors:  Rui Sun; Xu Wang; Jiajie Chen; Da Teng; Shixin Chan; Xucan Tu; Zhenglin Wang; Xiaomin Zuo; Xiang Wei; Li Lin; Qing Zhang; Xiaomin Zhang; Kechao Tang; Huabing Zhang; Wei Chen
Journal:  Front Genet       Date:  2022-09-06       Impact factor: 4.772

Review 5.  Calcium signaling in hepatitis B virus infection and its potential as a therapeutic target.

Authors:  Fanyun Kong; Fulong Zhang; Xiangye Liu; Suping Qin; Xiaoying Yang; Delong Kong; Xiucheng Pan; Hongjuan You; Kuiyang Zheng; Renxian Tang
Journal:  Cell Commun Signal       Date:  2021-08-06       Impact factor: 5.712

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.